Cefixime (advanced oral third-generation cephalosporin) and its place in clinical practice | CMAC

Cefixime (advanced oral third-generation cephalosporin) and its place in clinical practice

Clinical Microbiology and Antimicrobial Chemotherapy. 2025; 27(1):42-50

​ Avdeev S.N., Kozlov R.S., Svistushkin V.M., Sinopalnikov A.I., Zaitseva O.V., Zakharova I.N., Zyryanov S.K., Karpova E.P., Nikiforova G.N., Ryazantsev S.V., Andreeva I.V., Dekhnich A.V., Dovgan E.V., Stetsiouk O.U.
10.36488/cmac.2025.1.42-50
Section
Antimicrobials
Type
Expert opinion
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2025; 27(1):42-50

Abstract

On May 29, 2025, a meeting of the Expert Council «Cefixime (a modern oral 3rd generation cephalosporin from Sandoz) and its place in clinical practice» was held. The meeting included representatives of leading Russian research and educational medical institutions, leading experts in the field of antibiotic resistance, pulmonology, otolaryngology and pediatrics.

Sergey N. Avdeev

Federal State Autonomous Educational Institution of Higher Education "First Moscow State Medical University named after I.M. Sechenov" of the Ministry of Health of the Russian Federation

Roman S. Kozlov

Federal State Autonomous Educational Institution of Higher Education "Smolensk State Medical University" of the Ministry of Health of the Russian Federation

Svistushkin V.M.

Federal State Autonomous Educational Institution of Higher Education "Russian Medical Academy of Continuous Professional Education" of the Ministry of Health of the Russian Federation

Alexander I. Sinopalnikov

Federal State Autonomous Educational Institution of Higher Education "Russian University of Medicine" of the Ministry of Health of the Russian Federation

Zaitseva O.V.

Federal State Autonomous Educational Institution of Higher Education "Peoples' Friendship University of Russia"
State Budgetary Healthcare Institution "City Clinical Hospital No. 24" of the Moscow City Department of Healthcare

Zakharova I.N.

Federal State Autonomous Educational Institution of Higher Education "Russian Medical Academy of Continuous Professional Education" of the Ministry of Health of the Russian Federation

Zyryanov S.K.

Federal State Autonomous Educational Institution of Higher Education "First Moscow State Medical University named after I.M. Sechenov» of the Ministry of Health of the Russian Federation

Karpova E.P.

FGBOU VO «North-West State Medical University named after I.I. Mechnikov» of the Ministry of Health of the Russian Federation
Saint Petersburg Research Institute of Ear, Throat, Nose and Speech

Nikiforova G.N.

Research Institute of Antimicrobial Chemotherapy of the FGBOU VO SSMU of the Ministry of Health of the Russian Federation, Smolensk, Russia

Ryazantsev S.V.

Research Institute of Antimicrobial Chemotherapy of the FGBOU VO SSMU of the Ministry of Health of the Russian Federation, Smolensk, Russia

Irina V. Andreeva

OGBUZ «Smolensk Regional Clinical Hospital», Smolensk

Andrey V. Dekhnich

Research Institute of Antimicrobial Chemotherapy of the FGBOU VO SSMU of the Ministry of Health of the Russian Federation, Smolensk, Russia

Eugeniy V. Dovgan
Olga U. Stetsiouk
  • 1. Package leaflet – information for the patient. Skertzo, 400 mg, film-coated tablets. ЛП-№(008229)-(РГ-RU) dated 12/23/2024. Available at: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=5d670903-9bc3-4e0a-acf0-472c827b2fe4. Accessed June 2025. Russian.
  • 2. Package leaflet – information for the patient. Skertzo, 20 mg/ml, powder for preparation of oral suspension. ЛП-№(008249)-(РГ-RU) dated 12/24/2024. Available at: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=09ba7c8a-a9f1-4dac-8b51-1bb0b8fab399. Accessed June 2025. Russian.
  • 3. Brogden R.N., Campoli-Richards D.M. Cefixime. A review of its antibacterial activity. Pharmacokinetic properties and therapeutic potential. Drugs. 1989;38(4):524-550. DOI: 10.2165/00003495-198938040-00004
  • 4. Kozlov R.S., Ivanchik N.V., Skleenova E.Yu., Mikotina A.V., Azizov I.S., Trushin I.V., Dekhnich A.V. In vitro activity of cefpodoxime against Russian clinical isolates of Haemophilus influenzae, Streptococcus pneumoniae and Streptococcus pyogenes. Kliniceskaa mikrobiologia i antimikrobnaa himioterapia. 2023;25(4):372-378. Russian. DOI: 10.36488/cmac.2023.4.372-378
  • 5. Methodological Verification Center for Antimicrobial Resistance – Reference Center for Clinical Pharmacology. Analytical report. The state of antibiotic resistance of bacterial pathogens in the Russian Federation. 2024. Available at: https://www.antibiotic.ru/files/406/analiticheskij_otchet_202.pdf. Accessed June 2025. Russian.
  • 6. Kozlov R.S., Palagin I.S., Ivanchik N.V., Trushin I.V., Dekhnich A.V., Edelstein M.V., et al. National monitoring of antibiotic resistance of pathogens causing communityacquired urinary tract infections in Russia: results of the multicenter epidemiological study «DARMIS-2023». Kliniceskaa mikrobiologia i antimikrobnaa himioterapia. 2024;26(3):328-337. Russian. DOI: 10.36488/cmac.2024.3.328-337
  • 7. Jansen W.T., Verel A., Beitsma M., Verhoef J., Milatovic D. Longitudinal European surveillance study of antibiotic resistance of Haemophilus influenzae. J Antimicrob Chemother. 2006;58(4):873-877. DOI: 10.1093/jac/dkl310
  • 8. Shperling M.I., Shperling N.V., Neimark A.I., Kovaleva Yu.S. Modern approaches to diagnostics and treatment of urinary tract infections during pregnancy. Urology. 2024;(4):116-122. Russian. DOI: 10.18565/urology.2024.4.116-122
  • 9. Castle S.S. Cefixime. In: xPharm: The Comprehensive Pharmacology Reference. Eds. Enna S.J., Bylu D.B. Elsevier Inc., 2008.
  • 10. Ajmal M., Zamir A., Rehman A.U., Imran I., Saeed H., Majeed A., et al. Clinical pharmacokinetics of cefixime: a systematic review. Xenobiotica. 2023;53(3):149-162. DOI: 10.1080/00498254.2023.2217265
  • 11. General characteristics of the medicinal product. Skertzo, 400 mg, film-coated tablets. ЛП-№(008229)-(РГ-RU) dated 12/23/2024. Russian.
  • 12. General characteristics of the medicinal product. Skertso, 20 mg/ml, powder for preparation of suspension for oral administration. ЛП-№(008249)-(РГ-RU) dated 12/24/2024. Russian.
  • 13. Ministry of Health of the Russian Federation. Clinical guidelines. Urinary tract infection. Age category: children. 2024. Available at: https://cr.minzdrav.gov.ru/view-cr/281_3. Accessed June 2025. Russian.
  • 14. Ministry of Health of the Russian Federation. Clinical guidelines. Acute tonsillitis and pharyngitis (Acute tonsillopharyngitis). 2024. Available at: https://cr.minzdrav.gov.ru/view-cr/306_3. Accessed June 2025. Russian.
  • 15. Ministry of Health of the Russian Federation. Clinical guidelines. Acute sinusitis. 2024. Available at: https://cr.minzdrav.gov.ru/preview-cr/313_3. Accessed June 2025. Russian.
  • 16. Ministry of Health of the Russian Federation. Clinical guidelines. Acute otitis media. 2024. Available at: https://cr.minzdrav.gov.ru/view-cr/314_3. Accessed June 2025. Russian.
  • 17. Bluestone C.D., Stephenson J.S., Martin L.M. Ten-year review of otitis media pathogens. Pediatr Infect Dis J. 1992;11(8 Suppl.):S7-11. DOI: 10.1097/00006454-199208001-00002
  • 18. Fuji N., Salamone F.N., Kaur R., Bajorski P., Gonzalez E., Wang L., et al. Eighteen year longitudinal study of uncomplicated and complex acute otitis media during the pneumococcal conjugate vaccine era, 2006-2023. J Infect Dis. 2025 Mar 20:jiaf154. DOI: 10.1093/infdis/jiaf154
  • 19. Sánchez Arlegui A., Del Arco Rodríguez J., De Velasco Vázquez X., Gallego Rodrigo M., Gangoiti I., Mintegi S. Bacterial pathogens and antimicrobial resistance in acute otitis media. An Pediatr (Engl Ed). 2024;100(3):173-179. DOI: 10.1016/j.anpede.2023.12.013
  • 20. Fuji N., Pichichero M., Kaur R. Haemophilus influenzae prevalence, proportion of capsulated strains and antibiotic susceptibility during colonization and acute otitis media in children, 2019-2020. Pediatr Infect Dis J. 2021;40(9):792-796. DOI: 10.1097/INF.0000000000003171
  • 21. Kaur R., Fuji N., Pichichero M.E. Dynamic changes in otopathogens colonizing the nasopharynx and causing acute otitis media in children after 13-valent (PCV13) pneumococcal conjugate vaccination during 2015-2019. Eur J Clin Microbiol Infect Dis. 2022;41(1):37-44. DOI: 10.1007/s10096-021-04324-0
  • 22. Kaur R., Schulz S., Sherman A., Andrejko K., Kobayashi M., Pichichero M. Anticipated effects of higher-valency pneumococcal conjugate vaccines on colonization and acute otitis media. Pediatr Infect Dis J. 2024;43(10):1004-1010. DOI: 10.1097/INF.0000000000004413
  • 23. Dagan R., Leibovitz E. Bacterial eradication in the treatment of otitis media. Lancet Infect Dis. 2002;2(10):593-604. DOI: 10.1016/s1473-3099(02)00394-8
  • 24. Dagan R., Leibovitz E. Achieving bacterial eradication using pharmacokinetics pharmacodynamics principles. Int J Infect Dis. 2003;7:S21-S26. DOI: 10.1016/s1201-9712(03)90067-1
  • 25. Ministry of Health of the Russian Federation. Clinical guidelines «Chronic bronchitis», 2024. Available at: https://cr.minzdrav.gov.ru/view-cr/603_3. Accessed June 2025. Russian.
  • 26. Ministry of Health of the Russian Federation. Clinical guidelines «Chronic obstructive pulmonary disease (COPD)», 2024. Available at: https://cr.minzdrav.gov.ru/view-cr/603_3. Accessed June 2025. Russian.
  • 27. Ministry of Health of the Russian Federation. Clinical guidelines. Cystitis in women. 2024. Available at: https://cr.minzdrav.gov.ru/view-cr/14_3. Accessed June 2025. Russian.
  • 28. Ministry of Health of the Russian Federation. Clinical guidelines. Urinary tract infection during pregnancy. Available at: https://cr.minzdrav.gov.ru/view-cr/719_1. Accessed June 2025. Russian.
  • 29. Crider K.S., Cleves M.A., Reefhuis J., Berry R.J., HobbsC.A., Hu D.J. Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study. Arch Pediatr Adolesc Med. 2009;163(11):978-985. DOI: 10.1001/archpediatrics.2009.188
  • 30. Goldberg O., Moretti M., Levy A., Koren G. Exposure to nitrofurantoin during early pregnancy and congenital malformations: a systematic review and meta-analysis. J Obstet Gynaecol Can. 2015;37(2):150-156. DOI: 10.1016/S1701-2163(15)30337-6
  • 31. Ailes E.C., Summers A.D., Tran E.L., Gilboa S.M., Arnold K.E., Meaney-Delman D., Reefhuis J. Antibiotics dispensed to privately insured pregnant women with urinary tract infections – United States, 2014. MMWR Morb Mortal Wkly Rep. 2018;67(1):18-22. DOI: 10.15585/mmwr.mm6701a4
  • 32. Muanda F.T., Sheehy O., Bérard A. Use of antibiotics during pregnancy and the risk of major congenital malformations: a population based cohort study. Br J Clin Pharmacol. 2017;83(11):2557-2571. DOI: 10.1111/bcp.13364
  • 33. Zagursky R.J., Pichichero M.E. Cross-reactivity in β-Lactam allergy. J Allergy Clin Immunol Pract. 2018;6(1):72-81.e1. DOI: 10.1016/j.jaip.2017.08.027
  • 34. Castells M., Khan D.A., Phillips E.J. Penicillin allergy. N Engl J Med. 2019;381(24):2338-2351. DOI: 10.1056/NEJMra1807761
  • 35. Shenoy E.S., Macy E., Rowe T., Blumenthal K.G. Evaluation and management of penicillin allergy: a review. JAMA. 2019;321(2):188-199. DOI: 10.1001/jama.2018.19283
  • 36. Romano A., Atanaskovic-Markovic M., Barbaud A., Bircher A.J., Brockow K., Caubet J.C., et al. Towards a more precise diagnosis of hypersensitivity to beta-lactams – an EAACI position paper. Allergy. 2020;75(6):1300-1315. DOI: 10.1111/all.14122
Views
0 Abstract
0 PDF
0 Crossref citations
Shared